Table 4 Dose–response characteristics against HIV-1 infection of oral TAF in BLT hu-mice.

From: Fundamental aspects of long-acting tenofovir alafenamide delivery from subdermal implants for HIV prophylaxis

Pharmacodynamic parameter

Vaginal

Rectal

ED50 (µmol)

1.17

1.27

ED90 (µmol)

2.15

1.62

m-value ± SEM, R2

3.60 ± 0.22, 0.989

9.18 ± 1.94, 0.918

Back to article page